BridgeBio Pharma, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

BridgeBio Pharma, Inc. reported Cash And Cash Equivalents At Carrying Value of $570.12 million for the year ending 2025.

  • BridgeBio Pharma, Inc. showed a decrease of -16.3% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from BridgeBio Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
  • XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 9 years of available data (2017 to 2025), BridgeBio Pharma, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 519.7%.
  • Historical annual values: Fiscal year 2025: $570.12 million | Fiscal year 2024: $681.10 million | Fiscal year 2023: $375.94 million | Fiscal year 2022: $376.69 million | Fiscal year 2021: $393.77 million | Fiscal year 2020: $356.08 million | Fiscal year 2019: $363.77 million | Fiscal year 2018: $436.09 million | Fiscal year 2017: $92.00 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: